Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum SIGA Technologies Inc SIGA

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks, vaccines and therapies for emerging infectious diseases, and health preparedness. The Company's lead product is TPOXX, also known as tecovirimat and ST-246, an orally administered and... see more

NDAQ:SIGA - Post Discussion

SIGA Technologies Inc > SIGA’S SMALLPOX WIN IS NO MONKEY BUSINESS!
View:
Post by AviseAnalytics on May 26, 2022 7:53am

SIGA’S SMALLPOX WIN IS NO MONKEY BUSINESS!

 
$SIGA
 
Siga Technologies (NASDAQ: SIGA), a commercial-stage pharmaceutical company scored an FDA approval for its intravenous (IV) formulation of TPOXX® (tecovirimat) by the U.S. Food and Drug Administration (FDA). Given the rise of Monkeypox cases around the globe, can the Company leverage its expertise to make the most of the emerging opportunity?
 
https://www.aviseanalytics.com/sigas-smallpox-win-is-no-monkey-business/
 
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities